{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:31:26Z","timestamp":1786433486210,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82504160"],"award-info":[{"award-number":["82504160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370672"],"award-info":[{"award-number":["82370672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["BX20250259"],"award-info":[{"award-number":["BX20250259"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing University Jiangjin Hospital Internal Cultivation Project","award":["2025YCXM010"],"award-info":[{"award-number":["2025YCXM010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05732-6","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:10:29Z","timestamp":1786432229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A simplified MRI\u2011based risk score and nomogram to predict initial objective response in unresectable hepatocellular carcinoma treated with HAIC, targeted therapy, and immunotherapy: a multicenter study"],"prefix":"10.1007","author":[{"given":"Yi-Kang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Guo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-378X","authenticated-orcid":false,"given":"Hao-Yang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"3","key":"5732_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"5732_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"5732_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review. JAMA Oncol. 2024;10(3):395\u2013404.","journal-title":"JAMA Oncol"},{"key":"5732_CR4","doi-asserted-by":"publisher","first-page":"1430196","DOI":"10.3389\/fimmu.2024.1430196","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Yang B, Teng Z, Liu Y, Li D, Qu X. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis. Front Immunol. 2024;15:1430196.","journal-title":"Front Immunol"},{"key":"5732_CR5","doi-asserted-by":"crossref","unstructured":"Zang M, Hu X, Yuan G, Li R, Li W, Pang H, et al. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study. Int Immunopharmacol. 2023;125(Pt A):111019.","DOI":"10.1016\/j.intimp.2023.111019"},{"key":"5732_CR6","doi-asserted-by":"publisher","first-page":"1615506","DOI":"10.3389\/fonc.2025.1615506","volume":"15","author":"B Liu","year":"2025","unstructured":"Liu B, Yin L, Chen Y, Hou X, Li Y, Liu X, et al. Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC. Front Oncol. 2025;15:1615506.","journal-title":"Front Oncol"},{"issue":"6","key":"5732_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3892\/ol.2023.14121","volume":"26","author":"Z Li","year":"2023","unstructured":"Li Z, Xu Y, Qu W, Liu P, Zhu Y, Li H, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta\u2013analysis. Oncol Lett. 2023;26(6):534.","journal-title":"Oncol Lett"},{"key":"5732_CR8","doi-asserted-by":"publisher","first-page":"1364345","DOI":"10.3389\/fonc.2024.1364345","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, et al. Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis. Front Oncol. 2024;14:1364345.","journal-title":"Front Oncol"},{"issue":"9","key":"5732_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/MEG.0000000000003012","volume":"37","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Tao X, Zhang H, Shi X, Zhao H. Efficacy and safety of hepatic artery infusion chemotherapy conjunction with tyrosine kinase inhibitors and programmed death-1 inhibitors for unresectable\/advanced hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol. 2025;37(9):993\u20131002.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"5732_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12916-025-04110-1","volume":"23","author":"L Shen","year":"2025","unstructured":"Shen L, Cao F, Liu Y, Nuerhashi G, Lin L, Tan H, et al. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial. BMC Med. 2025;23(1):275.","journal-title":"BMC Med"},{"issue":"1","key":"5732_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8(1):413.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"5732_CR12","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1097\/JS9.0000000000000683","volume":"109","author":"QF Chen","year":"2023","unstructured":"Chen QF, Lyu N, Wang X, Jiang XY, Hu Y, Chen S, et al. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and\/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. Int J Surg. 2023;109(12):3929\u201339.","journal-title":"Int J Surg"},{"key":"5732_CR13","doi-asserted-by":"publisher","first-page":"112551","DOI":"10.1016\/j.intimp.2024.112551","volume":"138","author":"J Mei","year":"2024","unstructured":"Mei J, Yu C, Shi F, Guan R, Li S, Zhong C, et al. The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients. Int Immunopharmacol. 2024;138:112551.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"5732_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40644-025-00885-x","volume":"25","author":"C Lin","year":"2025","unstructured":"Lin C, Ren Y, Huang Y, Li S, Zhang J, Kang S, et al. Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma. Cancer Imaging. 2025;25(1):68.","journal-title":"Cancer Imaging"},{"key":"5732_CR15","doi-asserted-by":"crossref","unstructured":"Liu Z, Li X, Huang Y, Chang X, Zhang H, Wu X, et al. CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study. Hepatol Int. 2025.","DOI":"10.1007\/s12072-025-10877-5"},{"issue":"3","key":"5732_CR16","first-page":"709","volume":"48","author":"M Wu","year":"2025","unstructured":"Wu M, Que Z, Lai S, Li G, Long J, He Y, et al. Predicting the early therapeutic response to hepatic artery infusion chemotherapy in patients with unresectable HCC using a contrast-enhanced computed tomography-based habitat radiomics model: a multi-center retrospective study. Cellular oncology (Dordrecht, Netherlands). 2025;48(3):709\u201323.","journal-title":"Cellular oncology (Dordrecht, Netherlands)"},{"key":"5732_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mri.2022.01.006","volume":"88","author":"K Murase","year":"2022","unstructured":"Murase K, Kashiwagi N, Tomiyama N. Quantitative evaluation of simultaneous spatial and temporal regularization in dynamic contrast-enhanced MRI of the liver using Gd-EOB-DTPA. Magn Reson Imaging. 2022;88:25\u201337.","journal-title":"Magn Reson Imaging"},{"issue":"2","key":"5732_CR18","doi-asserted-by":"publisher","first-page":"e233229","DOI":"10.1148\/radiol.233229","volume":"314","author":"K Zhang","year":"2025","unstructured":"Zhang K, He K, Zhang L, Li WC, Xie SS, Cui YZ, et al. Gadoxetic Acid-enhanced MRI Scoring Model to Predict Pathologic Features of Hepatocellular Carcinoma. Radiology. 2025;314(2):e233229.","journal-title":"Radiology"},{"key":"5732_CR19","first-page":"e078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ (Clinical research ed). 2024;385:e078378.","journal-title":"BMJ (Clinical research ed)"},{"key":"5732_CR20","first-page":"m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE, Jr., Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ (Clinical research ed). 2020;368:m441.","journal-title":"BMJ (Clinical research ed)"},{"issue":"5","key":"5732_CR21","doi-asserted-by":"publisher","first-page":"e1001216","DOI":"10.1371\/journal.pmed.1001216","volume":"9","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216.","journal-title":"PLoS Med"},{"issue":"1","key":"5732_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao M, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int. 2024;18(1):4\u201331.","journal-title":"Hepatol Int"},{"issue":"1","key":"5732_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","volume":"18","author":"S Dai","year":"2025","unstructured":"Dai S, Chen Y, Cai W, Dong S, Zhao J, Chen L, et al. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. J Hematol Oncol. 2025;18(1):85.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5732_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72(2):288\u2013306.","journal-title":"J Hepatol"},{"issue":"1","key":"5732_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jhep.2012.02.016","volume":"57","author":"N Personeni","year":"2012","unstructured":"Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57(1):101\u20137.","journal-title":"J Hepatol"},{"issue":"4","key":"5732_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/bimj.200410135","volume":"47","author":"R Fluss","year":"2005","unstructured":"Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47(4):458\u201372.","journal-title":"Biom J"},{"key":"5732_CR27","doi-asserted-by":"publisher","first-page":"105948","DOI":"10.1016\/j.ijsu.2021.105948","volume":"89","author":"G Tang","year":"2021","unstructured":"Tang G, Qi L, Sun Z, Liu J, Lv Z, Chen L, et al. Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: A prospective two-center cohort study using LASSO-logistic regression. Int J Surg. 2021;89:105948.","journal-title":"Int J Surg"},{"issue":"6","key":"5732_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558\u201369.","journal-title":"Korean J Anesthesiol"},{"issue":"16","key":"5732_CR29","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1021\/acs.jmedchem.9b01101","volume":"63","author":"R Rodr\u00edguez-P\u00e9rez","year":"2020","unstructured":"Rodr\u00edguez-P\u00e9rez R, Bajorath J. Interpretation of Compound Activity Predictions from Complex Machine Learning Models Using Local Approximations and Shapley Values. J Med Chem. 2020;63(16):8761\u201377.","journal-title":"J Med Chem"},{"issue":"5","key":"5732_CR30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.chest.2023.06.038","volume":"164","author":"Y Jin","year":"2023","unstructured":"Jin Y, Kattan MW. Methodologic Issues Specific to Prediction Model Development and Evaluation. Chest. 2023;164(5):1281\u20139.","journal-title":"Chest"},{"issue":"11","key":"5732_CR31","first-page":"e49575","volume":"15","author":"JS Lopera Valle","year":"2023","unstructured":"Lopera Valle JS, Puello Correa DF, San\u00edn E. \u201cSix-and-Twelve\u201d Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Cureus. 2023;15(11):e49575.","journal-title":"Cureus"},{"issue":"3","key":"5732_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"1","key":"5732_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000488540","volume":"8","author":"H Rhee","year":"2019","unstructured":"Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features. Liver Cancer. 2019;8(1):24\u201340.","journal-title":"Liver Cancer"},{"issue":"1","key":"5732_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12880-021-00572-w","volume":"21","author":"M Zhou","year":"2021","unstructured":"Zhou M, Shan D, Zhang C, Nie J, Wang G, Zhang Y, et al. Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study. BMC Med Imaging. 2021;21(1):40.","journal-title":"BMC Med Imaging"},{"issue":"3","key":"5732_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jgh.12423","volume":"29","author":"A Nishie","year":"2014","unstructured":"Nishie A, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Ushijima Y, et al. Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(3):561\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"5732_CR36","doi-asserted-by":"crossref","unstructured":"Chen T, Zhai W, Song J, Liu W, Wu Z, Yang F, et al. Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes. MedComm (2020). 2025;6(12):e70494.","DOI":"10.1002\/mco2.70494"},{"issue":"19","key":"5732_CR37","doi-asserted-by":"publisher","first-page":"105617","DOI":"10.3748\/wjg.v31.i19.105617","volume":"31","author":"L Sierra","year":"2025","unstructured":"Sierra L, Abu-Hammour MN, Chatterjee A, Simons-Linares CR. Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma. World J Gastroenterol. 2025;31(19):105617.","journal-title":"World J Gastroenterol"},{"key":"5732_CR38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/JHC.S413283","volume":"10","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Liu J, Xiong Z, Gu S, Xia X. The Predictive Role of Inflammatory Biomarkers for Treatment Response and Progression-Free Survival in Patients with Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy with FOLFOX Regimen: A Preliminary Study. Journal of hepatocellular carcinoma. 2023;10:1037\u201349.","journal-title":"Journal of hepatocellular carcinoma"},{"issue":"1","key":"5732_CR39","doi-asserted-by":"publisher","first-page":"18147","DOI":"10.1038\/s41598-025-02960-6","volume":"15","author":"N Jiang","year":"2025","unstructured":"Jiang N, Zhan Y, Zhang S, Zhong B, Yang J, Yin Y, et al. Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization. Sci Rep. 2025;15(1):18147.","journal-title":"Sci Rep"},{"key":"5732_CR40","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2147\/JHC.S468843","volume":"11","author":"J Yang","year":"2024","unstructured":"Yang J, Zhang Y, Chen Y, Yang Y, Deng Y. Dynamic Changes of Neutrophil-to-Lymphocyte Ratio on Predicting Response of Immune Checkpoint Inhibitors Plus Targeted Therapies for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2024;11:1495\u2013505.","journal-title":"J Hepatocell Carcinoma"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05732-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:10:33Z","timestamp":1786432233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":40,"alternative-id":["5732"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05732-6","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}